TRAICK's recent funding round reveals both the promise and the gamble in medical AI: the company is in the pre-clearance phase with no FDA 510(k) or CE marking yet secured.
When TRAICK announced its $1.5 million seed round last November, the London-based healthtech startup joined a growing queue of companies convinced that artificial intelligence can make sense of ultrasound images faster—and perhaps better—than the radiologists who currently read them. The funding, which came from Turkey's iLab Ventures, is meant to push the company toward the regulatory finish line. But that finish line remains, for now, somewhere in the distance.
Founded in 2021, TRAICK develops software that analyzes thyroid and breast ultrasound scans for early signs of cancer. The platform automates what's known as TI-RADS scoring—a standardized system for assessing thyroid nodules—and spits out malignancy risk assessments in what the company claims is under 10 seconds. It's the kind of tool that could, in theory, ease bottlenecks in radiology departments stretched thin by staffing shortages and rising caseloads.
The catch? TRAICK doesn't yet have FDA 510(k) clearance or the CE marking required to sell medical devices in Europe. That puts the startup in a peculiar position: flush with seed capital to refine a product it can't yet commercialize.
A Quiet Round in a Noisy Space
iLab Ventures was the sole investor named in available coverage of the round, announced on November 11, 2025, and reported the same day by Turkish business outlets including Forbes Türkiye and Swipeline. The firm's portfolio page lists TRAICK alongside the startup's three co-founders: Dr. Burcu Bektaş Güneş, the CEO; Şahmeran Arıcan, who leads technology; and Prof. Dr. Düzgün Yıldırım, a radiologist serving as clinical lead.
The funding will go toward product development, clinical validation studies, and the regulatory marathon ahead—CE marking under the EU's Medical Device Regulation, and eventually, perhaps, an FDA submission. TRAICK operates with a lean team—LinkedIn lists 2–10 employees on the company page while showing 17 employees on its roster. (The discrepancy speaks, maybe, to the fluid nature of early-stage startups.) The company maintains offices in both London—at 284 Chase Road—and Istanbul, where Dr. Güneş also holds a faculty role at Istanbul Gedik University.
She represented TRAICK at CES in January, part of the startup's effort to raise its profile in a field that's become crowded quickly.
Late to a Race Already Underway
The ultrasound AI market isn't waiting around. See-Mode Technologies, a direct competitor in thyroid imaging, won FDA clearance for its SMART-T software in September 2024. Less than a year later, RadNet acquired the company for $8 million as part of its strategic expansion in AI-powered diagnostics. Koios Medical cleared the same regulatory bar back in 2021.
TRAICK, by contrast, is still in the pre-clearance phase. As of June 2026, the company hasn't published peer-reviewed validation studies, disclosed clinical performance metrics, or named hospital partners running pilot programs. That's not unusual for a seed-stage healthtech startup, but it does underscore the gap between where TRAICK is now and where it needs to be.
The startup did recently join the seventh cohort of Sanofi's PharmUp entrepreneurship program, according to a LinkedIn post earlier this year. And it's hiring: a radiology assistant position, listed recently, focuses on AI labeling and validation work under Prof. Yıldırım's supervision. Small signals, perhaps, that the clinical groundwork is underway.
The Regulatory Gauntlet
Medical AI is littered with companies that raised seed rounds, built promising prototypes, and then discovered that regulatory approval is less a hurdle than an endurance test. The FDA's 510(k) pathway—often called the "fast track"—still requires substantial clinical evidence, and Europe's post-2017 MDR regime has tightened requirements considerably. For a small team working across two countries, the logistical and financial burden isn't trivial.
As of June 2026, no valuation was disclosed in the coverage of TRAICK's round, nor were any co-investors beyond iLab identified. That suggests a relatively straightforward deal, but it also leaves open questions about what comes next. $1.5 million can fund validation studies and a regulatory submission, but commercial launch—particularly across multiple geographies—requires deeper pockets.
For now, TRAICK aims to clear regulatory barriers and enter the ultrasound AI market. Whether that bet pays off depends on how quickly the company can navigate the approval process, and whether the market it's chasing will still be open by the time it gets there.
